{"id":6528,"date":"2022-01-21T17:40:30","date_gmt":"2022-01-21T14:40:30","guid":{"rendered":"http:\/\/www.ced.org.tr\/?p=6528"},"modified":"2025-06-16T12:07:41","modified_gmt":"2025-06-16T09:07:41","slug":"rapor-surelerinin-uzatilmasi-hakkinda-sgk-duyurusu-21-ocak-2022","status":"publish","type":"post","link":"http:\/\/www.ced.org.tr\/?p=6528","title":{"rendered":"Rapor S\u00fcrelerinin Uzat\u0131lmas\u0131 Hakk\u0131nda SGK Duyurusu &#8211; 21 Ocak 2022"},"content":{"rendered":"\n<p>&nbsp;<strong>T.C. SOSYAL G\u00dcVENL\u0130K KURUMU BA\u015eKANLI\u011eI Genel Sa\u011fl\u0131k Sigortas\u0131 Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc&nbsp;<\/strong><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>&nbsp;21.01.2022&nbsp;<\/p>\n\n\n\n<p><strong>DUYURU&nbsp;<\/strong><\/p>\n\n\n\n<p>KRON\u0130K HASTALI\u011eI NEDEN\u0130YLE SA\u011eLIK RAPORU OLAN HASTALARIN \u0130LA\u00c7 VE TIBB\u0130 C\u0130HAZ TEM\u0130N\u0130 HAKKINDA&nbsp;<\/p>\n\n\n\n<p>Bilindi\u011fi \u00fczere Koronavir\u00fcs (Covid-19) nedeniyle vatanda\u015flar\u0131m\u0131z\u0131n sa\u011fl\u0131k hizmetine eri\u015fiminde aksamaya neden olunmamas\u0131 ve olas\u0131 bula\u015f riskinin azalt\u0131lmas\u0131 amac\u0131yla Kurumumuz taraf\u0131ndan sa\u011fl\u0131k raporlar\u0131n\u0131n s\u00fcresine ve bu raporlara istinaden re\u00e7etesiz temin edilecek ila\u00e7lara ili\u015fkin Kurumumuz internet sitesinde yay\u0131mlanan 18.03.2020 tarihli ve 28.08.2020 tarihli duyurular ile bilgilendirmeler yap\u0131lm\u0131\u015f ve bu kapsamda 01.01.2020 tarihi itibar\u0131 ile sonlanm\u0131\u015f veya bu tarihten sonra sonlanacak olan kronik hastal\u0131k raporlar\u0131n\u0131n s\u00fcresi uzat\u0131larak vatanda\u015flar\u0131m\u0131z\u0131n do\u011frudan eczanelerden ila\u00e7 temini yapmas\u0131 sa\u011flanm\u0131\u015ft\u0131r.&nbsp;<\/p>\n\n\n\n<p>Kurumumuz internet sitesinde yay\u0131mlanan 29.11.2021 tarihli duyuru ile baz\u0131 hastal\u0131klar i\u00e7in re\u00e7etesiz ila\u00e7 temin edilmesine son verilmi\u015f olup 28.02.2022 tarihinde a\u015fa\u011f\u0131da yer alan ila\u00e7 gruplar\u0131 i\u00e7in de re\u00e7etesiz ila\u00e7 temin edilmesine son verilecek, bunun d\u0131\u015f\u0131nda kalan ila\u00e7lara ait raporlar\u0131n s\u00fcreleri ise 30.04.2022 tarihine dek uzat\u0131larak re\u00e7etesiz ila\u00e7 temini uygulamas\u0131na devam edilecektir.&nbsp;<\/p>\n\n\n\n<p>Re\u00e7etesiz t\u0131bbi cihaz teminine ili\u015fkin olarak 20.03.2020 tarihli duyuru ekinde yer alan t\u0131bbi malzemelerin rapor s\u00fcreleri 30.04.2022 tarihine kadar uzat\u0131lm\u0131\u015f olup ilgili malzemelerin re\u00e7etesiz teminine devam edilecektir.&nbsp;<\/p>\n\n\n\n<p>Bu kapsamda, a\u015fa\u011f\u0131da belirtilen gruplar i\u00e7in de s\u00fcresi uzat\u0131lan sa\u011fl\u0131k raporlar\u0131n\u0131n 28.02.2022 tarihine kadar yenilenmesi gerekmekte olup bu tarih itibariyle Kurum taraf\u0131ndan s\u00fcresi uzat\u0131lan raporlar ge\u00e7ersiz say\u0131lacak ve bu gruplar i\u00e7in re\u00e7etesiz ila\u00e7 teminine son verilecektir.&nbsp;<\/p>\n\n\n\n<p>01.03.2022 tarihinden itibaren bu grup ila\u00e7lar\u0131n temini yeni d\u00fczenlenecek rapor ve bu rapora istinaden d\u00fczenlenecek re\u00e7ete ile m\u00fcmk\u00fcn olacak olup halen s\u00fcresi devam eden sa\u011fl\u0131k raporlar\u0131na istinaden ila\u00e7lar ise re\u00e7ete kar\u015f\u0131l\u0131\u011f\u0131nda temin edilebilecektir.&nbsp;<\/p>\n\n\n\n<p>1) 4.2.12 &#8211; \u0130mm\u00fcnglobulinlerin kullan\u0131m ilkeleri&nbsp;<\/p>\n\n\n\n<p>2) 4.2.13 &#8211; Hepatit tedavisi<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>3) 4.2.14 &#8211; Kanser tedavisinde ila\u00e7 kullan\u0131m ilkeleri&nbsp;<\/p>\n\n\n\n<p>4) 4.2.15 &#8211; Klopidogrel, silostazol, ivabradin, prasugrel, dabigatran, rivaroksaban, apiksaban, tikagrelor ve ranolazin kullan\u0131m ilkeleri&nbsp;<\/p>\n\n\n\n<p>5) 4.2.18 &#8211; Orlistat kullan\u0131m ilkeleri&nbsp;<\/p>\n\n\n\n<p>6) 4.2.27 &#8211; Fakt\u00f6r ve di\u011fer kan \u00fcr\u00fcnlerinin re\u00e7ete edilme ilkeleri&nbsp;<\/p>\n\n\n\n<p>7) 4.2.30 &#8211; Pulmoner hipertansiyon ile kronik tromboembolik pulmoner hipertansiyonda ila\u00e7 kullan\u0131m ilkeleri&nbsp;<\/p>\n\n\n\n<p>8) 4.2.33.D &#8211; G\u00f6z hastal\u0131klar\u0131 tedavisinde kullan\u0131lan di\u011fer ila\u00e7lar&nbsp;<\/p>\n\n\n\n<p>9) 4.2.34 \u2013 Multipl Skleroz Hastal\u0131\u011f\u0131nda fampiridin, beta interferon, glatiramer asetat, teriflunomid, dimetil fumarat, fingolimod, okrelizumab, kladribin, natalizumab ve alemtuzumab kullan\u0131m ilkeleri&nbsp;<\/p>\n\n\n\n<p>10) Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 Renkli Re\u00e7ete Sistemi\u2019ne dahil ila\u00e7lar&nbsp;<\/p>\n\n\n\n<p>T\u00fcm ilgililere \u00f6nemle duyurulur.\u00a0<\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"http:\/\/www.ced.org.tr\/wp-content\/uploads\/2022\/01\/418-2Duyuru.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"418-2Duyuru g\u00f6m\u00fcs\u00fc. g\u00f6m\u00fcs\u00fc.\"><\/object><a href=\"http:\/\/www.ced.org.tr\/wp-content\/uploads\/2022\/01\/418-2Duyuru.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">418-2Duyuru<\/a><a href=\"http:\/\/www.ced.org.tr\/wp-content\/uploads\/2022\/01\/418-2Duyuru.pdf\" class=\"wp-block-file__button\" download>\u0130ndir<\/a><\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>KRON\u0130K HASTALI\u011eI NEDEN\u0130YLE SA\u011eLIK RAPORU OLAN HASTALARIN \u0130LA\u00c7 VE TIBB\u0130 C\u0130HAZ TEM\u0130N\u0130 HAKKINDA\u00a0<\/p>\n","protected":false},"author":1,"featured_media":6459,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1,1234,64,62],"tags":[],"class_list":["post-6528","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ced","category-duyuru","category-mevzuat","category-sagliktan-haberler"],"aioseo_notices":[],"jetpack_featured_media_url":"http:\/\/www.ced.org.tr\/wp-content\/uploads\/2021\/07\/CEDLOGO.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts\/6528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6528"}],"version-history":[{"count":2,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts\/6528\/revisions"}],"predecessor-version":[{"id":6531,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts\/6528\/revisions\/6531"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/media\/6459"}],"wp:attachment":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6528"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}